doi: 10.1016/s0378-4347(00)81267-0.
Paired-ion chromatographic analysis of tamoxifen and two major metabolites in plasma
- PMID: 7364914
- DOI: 10.1016/s0378-4347(00)81267-0
Item in Clipboard
Paired-ion chromatographic analysis of tamoxifen and two major metabolites in plasma
J Chromatogr.
.
Abstract
A method is described for the clinical analysis of the non-steroidal anti-estrogenic, antineoplastic agent, tamoxifen and its 4-hydroxy and N-desmethyl metabolites in human plasma. The analytes are extracted from biological fluid with diethyl ether and subsequently converted to fluorescent phenanthrene derivatives by irradiation with UV light. The fluorophores are separated by paired-ion chromatography on a reversed-phase (C18) column. Spectrofluorometric monitoring of the column eluent allows quantitation of analytes as their phenanthrene derivatives to levels of 100 pg/ml of plasma.
Similar articles
-
Clinical analysis of tamoxifen, an anti-neoplastic agent, in plasma.Clin Chem. 1978 Sep;24(9):1518-24. Clin Chem. 1978. PMID: 688611
-
Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography.J Chromatogr B Biomed Appl. 1994 May 13;655(2):261-8. doi: 10.1016/0378-4347(94)00054-9. J Chromatogr B Biomed Appl. 1994. PMID: 8081472
-
An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Dec 15;878(32):3402-14. doi: 10.1016/j.jchromb.2010.10.027. Epub 2010 Oct 30. J Chromatogr B Analyt Technol Biomed Life Sci. 2010. PMID: 21094101
-
Determination of tamoxifen and its main metabolites in plasma samples from breast cancer patients by micellar liquid chromatography.Talanta. 2015 Jan;131:535-40. doi: 10.1016/j.talanta.2014.07.093. Epub 2014 Aug 20. Talanta. 2015. PMID: 25281137
-
Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques.J Pharm Biomed Anal. 2011 Jun 1;55(3):518-26. doi: 10.1016/j.jpba.2011.02.009. Epub 2011 Feb 18. J Pharm Biomed Anal. 2011. PMID: 21392921 Review.
Cited by
-
New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.Steroids. 2007 Nov;72(13):829-42. doi: 10.1016/j.steroids.2007.07.009. Epub 2007 Jul 27. Steroids. 2007. PMID: 17765940 Free PMC article. Review.
-
Evaluation of tamoxifen and metabolites by LC-MS/MS and HPLC methods.Br J Biomed Sci. 2014;71(1):33-9. doi: 10.1080/09674845.2014.11669960. Br J Biomed Sci. 2014. PMID: 24693573 Free PMC article.
-
Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer.Breast Cancer Res Treat. 1993 Dec;28(3):241-50. doi: 10.1007/BF00666585. Breast Cancer Res Treat. 1993. PMID: 8018953 Clinical Trial.
-
The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole.Breast Cancer Res Treat. 1988 Jul;11(3):197-209. doi: 10.1007/BF01807278. Breast Cancer Res Treat. 1988. PMID: 3048447
-
The bioavailability of Tamoplex (tamoxifen). Part 3. A steady-state study in breast cancer patients.Pharm Weekbl Sci. 1988 Feb 19;10(1):22-5. doi: 10.1007/BF01966431. Pharm Weekbl Sci. 1988. PMID: 3353207